Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW; Initiative on Crohn's and Colitis, The Netherlands. van der Woude CJ, et al. Among authors: paradowski l. Inflamm Bowel Dis. 2010 Oct;16(10):1708-16. doi: 10.1002/ibd.21252. Inflamm Bowel Dis. 2010. PMID: 20848453 Clinical Trial.
A phase II study of laquinimod in Crohn's disease.
D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. D'Haens G, et al. Gut. 2015 Aug;64(8):1227-35. doi: 10.1136/gutjnl-2014-307118. Epub 2014 Oct 3. Gut. 2015. PMID: 25281416 Free PMC article. Clinical Trial.
Paraoxonase-1 status in Crohn's disease and ulcerative colitis.
Boehm D, Krzystek-Korpacka M, Neubauer K, Matusiewicz M, Berdowska I, Zielinski B, Paradowski L, Gamian A. Boehm D, et al. Among authors: paradowski l. Inflamm Bowel Dis. 2009 Jan;15(1):93-9. doi: 10.1002/ibd.20582. Inflamm Bowel Dis. 2009. PMID: 18626964
Enhanced formation of advanced oxidation protein products in IBD.
Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L, Gamian A. Krzystek-Korpacka M, et al. Among authors: paradowski l. Inflamm Bowel Dis. 2008 Jun;14(6):794-802. doi: 10.1002/ibd.20383. Inflamm Bowel Dis. 2008. PMID: 18213700
Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Wittmann T, et al. Among authors: paradowski l. Aliment Pharmacol Ther. 2010 Mar;31(6):615-24. doi: 10.1111/j.1365-2036.2009.04216.x. Epub 2009 Dec 10. Aliment Pharmacol Ther. 2010. PMID: 20003095 Free article. Clinical Trial.
Economic implications of biological therapy for Crohn's disease.
Petryszyn PW, Paradowski L. Petryszyn PW, et al. Among authors: paradowski l. Prz Gastroenterol. 2015;10(4):197-202. doi: 10.5114/pg.2015.55749. Epub 2015 Nov 23. Prz Gastroenterol. 2015. PMID: 26759625 Free PMC article. Review.
98 results